期刊文献+

831例万古霉素类药物利用分析 被引量:13

Analysis on the utilization of 831 cases of Vancomycin using
下载PDF
导出
摘要 目的:了解万古霉素类药物的合理应用情况。方法:采用回顾性调查方法,抽取北京市地方及部队13家医院791份患者病历,分析应用万古霉素类831例次的药物利用情况。结果:治疗用药30.32%,预防用药54.87%。不合理用药病例占32.93%,其消耗金额均值明显高于其它病例。预防用药的不合理比例(36.18%)明显高于治疗用药(21.65%)。不良反应发生率3.01%。结论:万古霉素类药物目前的应用范围有所放宽,应限制预防性用药,实施保护性应用。 Objective:To investigate the rational utilization of Vancomycins.Methods: The utilization of 831 cases using Vancomyein from 13 hospital in Beijing was analysed by using retrospective analysis technique.Results: There were 30.32% of the cases for therapy and 54.87% for prevention.The rate of unreasonable cases was 32.93% and it took more money than the reasonable cases.The unreasonable rate of preventive cases(36.18%) was higher than that of therapeutic cases(21.65%).There were 25 cases of ADR(3.01%).Conclusions: It is necessary to limit the preventive use of Vancomycin and improve the level of rational utilization.
出处 《中国药物应用与监测》 CAS 2004年第1期55-57,共3页 Chinese Journal of Drug Application and Monitoring
关键词 万古霉素 药物利用 合理用药 Vancomycin Drug utilization Reasonable use of drugs
  • 相关文献

参考文献4

二级参考文献50

  • 1殷凯生 见:殷凯生 殷民生.免疫功能低下患者抗感染药物的应用[A].见:殷凯生,殷民生.实用抗感染药物手册[C].北京:人民卫生出版社,2001.463-485.
  • 2汤光 沈素 李任 陈新谦 金有豫.抗微生物药物[A].陈新谦,金有豫.新编药物学: 第15版[C].北京:人民卫生出版社,2002.94.
  • 3[1]Hirnatsu K, Hanaki H, Iro T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. [J]. J Antimicrob Chemother,1997,40(1): 135
  • 4[2]
  • 5[3]Sieradzko K, Villari P, Tomasz A. Decreased susceptibilities to teicomycin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of Staphylococci.[J]. Antimicrob Agents Chemother, 1998, 42(1): 100
  • 6[4]Poyart C, Pierre C, Quesne G, et al. Emergence of vancomycin resistance in the genus Streptococcus: Characterization of a vanB transferable determinant in Streptococcus bovis, [J]. Antimicrob Agents Chemother, 1997, 41(1):24
  • 7[5]Ligozzi M, Cascio GL, Fontana R. vanA gene cluster in a vancomycin-resistant clinical isolate of Bacillus circulans.[J]. Antimicrob Agents Chemother, 1998, 42(8): 2055
  • 8[6]Parenti F, Cavalleri. Novel glycopeptide antibiotics of the dalbaheptide group. [J]. Drug Fut, 1990, 15(1): 57
  • 9[7]Yan,H-S, Qi D-F, Cheng X-H,et al. Antibiotic activities and affinityes for bacterial cell wall analogue of Ndemethylvancomycin and its derivaties. [J]. J Antibiotics,1998,51(8):750
  • 10[8]Allen NE, LeTourneau D, Hobbs JN. The role of hydrophobic chain as antibacterial activity of semisynthetic glycopeptide antibiotics. [J]. J Antibiotics, 1997, 50(8):675

共引文献263

同被引文献62

引证文献13

二级引证文献63

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部